Recent Finacing
Recent Raise
Fusion Pharmaceuticals develops targeted alpha-particle radiotherapeutics for cancer, combining antibody targeting with isotope payloads, using a Fast-Clear linker to clear unbound isotopes, and expanding pipeline via discovery and in‑licensing.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors